Barclays Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 63.4%

Neg 63.4% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $56 to $55.